Mutation of the LXCXE Binding Cleft of pRb Facilitates Transformation by ras In Vitro but Does Not Promote Tumorigenesis In Vivo

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Talluri, Srikanth ^a   Francis, Sarah M ^a   Dick, Frederick A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; K RAS PROTEIN; PROTEIN P21; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL AGING; CELL PROLIFERATION; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; GENE MUTATION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE RAS; PROTEIN EXPRESSION; RB GENE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BINDING SITES; CARCINOGENESIS; CELL AGING; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; CLONE CELLS; DNA DAMAGE; GENE EXPRESSION REGULATION; HYPERPLASIA; LUNG; LUNG NEOPLASMS; MICE; MUTATION; ONCOGENES; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881152805     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072236     Document Type: Article

References (43)

1. Campisi J, (2001) Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 11: S27-S31. doi:10.1016/S0962-8924(01)02151-1. PubMed: 11684439.
2. Collado M, Serrano M, (2010) Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10: 51-57. doi:10.1038/nrc2772. PubMed: 20029423.
3. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720-724. doi:10.1038/nature03890. PubMed: 16079850.
4. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730. doi:10.1038/nature03918. PubMed: 16079851.
5. Campisi J, (2005) Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120: 513-522. doi:10.1016/j.cell.2005.02.003. PubMed: 15734683.
6. Campisi J, d'Adda di Fagagna F, (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740. doi:10.1038/nrg2208. PubMed: 17667954.
7. Dankort D, Filenova E, Collado M, Serrano M, Jones K, et al. (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379-384. doi:10.1101/gad.1516407. PubMed: 17299132.
8. Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, et al. (2009) Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28: 2289-2298. doi:10.1038/onc.2009.95. PubMed: 19398955.
9. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, et al. (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9: 493-505. doi:10.1038/ncb1567. PubMed: 17450133.
10. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, et al. (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660-665. doi:10.1038/nature03841. PubMed: 16079837.
11. Narita M, (2007) Cellular senescence and chromatin organisation. Br J Cancer 96: 686-691. doi:10.1038/sj.bjc.6603636. PubMed: 17311013.
12. Narita M, Nũnez S, Heard E, Narita M, Lin AW, et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716. doi:10.1016/S0092-8674(03)00401-X. PubMed: 12809602.
13. Chandra T, Kirschner K, Thuret JY, Pope BD, Ryba T, et al. (2012) Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Mol Cell 47: 203-214. doi:10.1016/j.molcel.2012.06.010. PubMed: 22795131.
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. doi:10.3322/CA.2007.0010. PubMed: 18287387.
15. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380. doi:10.1056/NEJMra0802714. PubMed: 18815398.
16. Rodenhuis S, Slebos RJ, (1990) The ras oncogenes in human lung cancer. Am Rev Respir Dis 142: S27-S30. doi:10.1164/ajrccm/142.6_Pt_2.S27. PubMed: 2252272.
17. Meuwissen R, Berns A, (2005) Mouse models for human lung cancer. Genes Dev 19: 643-664. doi:10.1101/gad.1284505. PubMed: 15769940.
18. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248. doi:10.1101/gad.943001. PubMed: 11751630.
19. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A, (2001) Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20: 6551-6558. doi:10.1038/sj.onc.1204837. PubMed: 11641780.
20. DuPage M, Dooley AL, Jacks T, (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4: 1064-1072. doi:10.1038/nprot.2009.95. PubMed: 19561589.
21. Sherr CJ, McCormick F, (2002) The RB and p53 pathways in cancer. Cancer Cell 2: 103-112. doi:10.1016/S1535-6108(02)00102-2. PubMed: 12204530.
22. Wistuba II, Gazdar AF, Minna JD, (2001) Molecular genetics of small cell lung carcinoma. Semin Oncol 28: 3-13. doi:10.1016/S0093-7754(01)90052-1. PubMed: 11479891.
23. Dick FA, Rubin SM, (2013) Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 14: 297-306. doi:10.1038/nrm3567. PubMed: 23594950.
24. Talluri S, Isaac CE, Ahmad M, Henley SA, Francis SM, et al. (2010) A G1 checkpoint mediated by the retinoblastoma protein that is dispensable in terminal differentiation but essential for senescence. Mol Cell Biol 30: 948-960. doi:10.1128/MCB.01168-09. PubMed: 20008551.
25. Ho VM, Schaffer BE, Karnezis AN, Park KS, Sage J, (2009) The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene 28: 1393-1399. doi:10.1038/onc.2008.491. PubMed: 19151761.
26. Isaac CE, Francis SM, Martens AL, Julian LM, Seifried LA, et al. (2006) The retinoblastoma protein regulates pericentric heterochromatin. Mol Cell Biol 26: 3659-3671. doi:10.1128/MCB.26.9.3659-3671.2006. PubMed: 16612004.
27. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444: 638-642. doi:10.1038/nature05327. PubMed: 17136094.
28. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, et al. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633-637. doi:10.1038/nature05268. PubMed: 17136093.
29. Mallette FA, Ferbeyre G, (2007) The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 6: 1831-1836. doi:10.4161/cc.6.15.4516. PubMed: 17671427.
30. Lara MF, Paramio JM, (2007) The Rb family connects with the Tp53 family in skin carcinogenesis. Mol Carcinog 46: 618-623. doi:10.1002/mc.20338. PubMed: 17486638.
31. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, et al. (2004) PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13: 523-535. doi:10.1016/S1097-2765(04)00062-0. PubMed: 14992722.
32. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, et al. (2000) PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14: 2015-2027. PubMed: 10950866.
33. Bernardi R, Pandolfi PP, (2003) Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22: 9048-9057. doi:10.1038/sj.onc.1207106. PubMed: 14663483.
34. Quintanilla M, Brown K, Ramsden M, Balmain A, (1986) Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80. doi:10.1038/322078a0. PubMed: 3014349.
35. Pazzaglia S, Mancuso M, Primerano B, Rebessi S, Biozzi G, et al. (2001) Analysis of c-Ha-ras gene mutations in skin tumors induced in carcinogenesis-susceptible and carcinogenesis-resistant mice by different two-stage protocols or tumor promoter alone. Mol Carcinog 30: 111-118. doi:10.1002/1098-2744(200102)30:2. PubMed: 11241758.
36. Fikaris AJ, Lewis AE, Abulaiti A, Tsygankova OM, Meinkoth JL, (2006) Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling. J Biol Chem 281: 34759-34767. doi:10.1074/jbc.M606737200. PubMed: 16968694.
37. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G, (2007) The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 21: 43-48. doi:10.1101/gad.1487307. PubMed: 17210786.
38. Di Micco R, Sulli G, Dobreva M, Liontos M, Botrugno OA, et al. (2011) Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol 13: 292-302. doi:10.1038/ncb2170. PubMed: 21336312.
39. Coschi CH, Martens AL, Ritchie K, Francis SM, Chakrabarti S, et al. (2010) Mitotic chromosome condensation mediated by the retinoblastoma protein is tumor-suppressive. Genes Dev 24: 1351-1363. doi:10.1101/gad.1917610. PubMed: 20551166.
40. Francis SM, Chakrabarti S, Dick FA, (2011) A context-specific role for retinoblastoma protein-dependent negative growth control in suppressing mammary tumorigenesis. PLOS ONE 6: e16434. doi:10.1371/journal.pone.0016434. PubMed: 21364977.
41. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, et al. (2004) Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 64: 2307-2316. doi:10.1158/0008-5472.CAN-03-3376. PubMed: 15059877.
42. Hurford RK Jr., Cobrinik D, Lee MH, Dyson N, (1997) pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev 11: 1447-1463. doi:10.1101/gad.11.11.1447. PubMed: 9192872.
43. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW, (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602. doi:10.1016/S0092-8674(00)81902-9. PubMed: 9054499.